Fosun Pharma: Subsidiary obtains registration approval for new indications of drugs.

Fosun Pharma announced that the drug registration application for the new indication of Sulinumab Injection independently developed by its holding subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary, has been approved by the National Medical Products Administration. The newly approved indication is for the adjuvant treatment of gastric cancer that is operable and can be surgically resected with PD-L1 expression CPS5, in combination with oxaliplatin and paclitaxel or as a single-agent adjuvant therapy after surgery.